Fineline Cube

Follow:
14483 Articles
Pfizer Partners with CR Pharma to Expand Cancer Drug Access in China
CompanyDrug

Pfizer Partners with CR Pharma to Expand Cancer Drug Access in China

Roche’s Evrysdi Receives Patent Term Extension in China, Extending Protection to 2035
Legal / IP

Roche’s Evrysdi Receives Patent Term Extension in China, Extending Protection to 2035

CanSino Biologics' Menhycia Vaccine Aims to Expand Age Range with NMPA Filing
CompanyDrug

CanSino Biologics’ Menhycia Vaccine Aims to Expand Age Range with NMPA Filing

Jiangsu Hengrui Medicine's SHR-1819 Receives NMPA Approval for Atopic Dermatitis Clinical Trial
CompanyDrug

Jiangsu Hengrui Medicine’s SHR-1819 Receives NMPA Approval for Atopic Dermatitis Clinical Trial

AstraZeneca's Truqap Meets Primary Endpoint in Phase III Prostate Cancer Study
CompanyDrug

AstraZeneca’s Truqap Meets Primary Endpoint in Phase III Prostate Cancer Study

Sichuan Huiyu Pharmaceutical's HY-2003 Approved for Clinical Trials by China's NMPA
CompanyDrug

Sichuan Huiyu Pharmaceutical’s HY-2003 Approved for Clinical Trials by China’s NMPA

J&J's Stelara Faces New Biosimilar Competition in China with CSPC Pharmaceutical's Entry
CompanyDrug

J&J’s Stelara Faces New Biosimilar Competition in China with CSPC Pharmaceutical’s Entry

AstraZeneca's ALXN1850 (Efzimfotase Alfa) Selected for China's Rare Disease Care Plan
CompanyDeals

AstraZeneca’s ALXN1850 (Efzimfotase Alfa) Selected for China’s Rare Disease Care Plan

Amgen's MariTide Showcases Significant Weight Loss in Phase II Study
CompanyDrug

Amgen’s MariTide Showcases Significant Weight Loss in Phase II Study

VectorBuilder and Zhejiang Dapu Biotechnology Form Partnership to Advance Biotech Innovation
CompanyDeals

VectorBuilder and Zhejiang Dapu Biotechnology Form Partnership to Advance Biotech Innovation

Roche's SKYSCRAPER-01 Study: Tiragolumab-Tecentriq Combo Misses Primary Endpoint in NSCLC
CompanyDrug

Roche’s SKYSCRAPER-01 Study: Tiragolumab-Tecentriq Combo Misses Primary Endpoint in NSCLC

Roche to Acquire Poseida Therapeutics in a USD 1.5 Billion Deal
CompanyDeals

Roche to Acquire Poseida Therapeutics in a USD 1.5 Billion Deal